EUVIMEDEUVIMED entdecken
Crossref

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Charlotte L B M Korst, Sabrin Tahri iD, Carolien Duetz, Wassilis S C Bruins iD, A Vera de Jonge iD, Madelon E de Jong iD, Cathelijne Fokkema iD, Febe Smits, Kaz Groen, Christie P M Verkleij, Kristine A Frerichs iD, Natalie Papazian und 23 weitere

Blood · 19.06.2025 · 145 (25) · 3007-3014

DOI: 10.1182/blood.2024026455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 19.06.2025. Verfasst von Charlotte L B M Korst und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Multiple Myeloma, Killer Cells, Natural, Antibodies, Monoclonal, Bone Marrow Cells. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are important effector cells in antibody-based immune therapies for multiple myeloma (MM) through antibody-dependent cellular cytotoxicity. Here, we used single-cell transcriptomics, flow cytometry, and functional assays to investigate the bone marrow NK-cell compartment of patients with MM at diagnosis and during treatment. We show reduced proportion of CD16+ cytotoxic NK cells in a subset of patients at diagnosis, which correlated with decreased cytokine production and NK-cell degranulation against MM cells in the presence of the anti-CD38 antibody daratumumab. In line with these findings, a low proportion of CD16+ bone marrow NK cells at diagnosis was associated with a reduced likelihood of achieving measurable (or minimal) residual disease (MRD) negativity after consolidation in patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone in conjunction with autologous stem cell transplantation in the CASSIOPEIA trial. In contrast, NK-cell distribution did not predict MRD negativity in patients treated in the control arm without daratumumab. These findings highlight the impact of the bone marrow NK-cell compartment on therapeutic outcomes in patients with MM receiving immunotherapy with CD38-targeting antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaKiller Cells, NaturalAntibodies, MonoclonalBone Marrow CellsHumansNeoplasm, ResidualDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsFemaleMaleMiddle AgedBone MarrowADP-ribosyl Cyclase 1BortezomibThalidomideAged

Substanzen

daratumumabAntibodies, MonoclonalDexamethasoneADP-ribosyl Cyclase 1BortezomibThalidomide

Autor:innen und Institutionen

  • Department of Hematology, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Division of Hematology 1, Azienda Ospedaliero-Universitaria Citta della salute e della Scienza, Department of Molecular Biotechnology and Health Science, University of Torino, Turin, Italy.
  • Department of Immunology, Laboratory Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.

ORCID-Profile: Sabrin Tahri, Wassilis S C Bruins, A Vera de Jonge, Madelon E de Jong, Cathelijne Fokkema, Kristine A Frerichs, Gregory van Beek, Thomas Baardemans, Giada Dal Collo, Rosa Rentenaar, Vincent H J van der Velden, Mathijs A Sanders, Francesca Gay, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Tom Cupedo, Niels W C J van de Donk

Zitieren

APA

Korst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., Frerichs, K. A., Papazian, N., van Duin, M., van Beek, G., Hoogenboezem, R., Baardemans, T., Dal Collo, G., Stoetman, E. C. G., Cosovic, M., …, & van de Donk, N. W. C. J. (2025). The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy. Blood, 145(25), 3007-3014. https://doi.org/10.1182/blood.2024026455

Vancouver

Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong ME, et al. The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy. Blood. 2025;145(25):3007-3014. doi:10.1182/blood.2024026455

BibTeX
@article{Korst2025,
  author = {Korst, Charlotte L B M and Tahri, Sabrin and Duetz, Carolien and Bruins, Wassilis S C and de Jonge, A Vera and de Jong, Madelon E and Fokkema, Cathelijne and Smits, Febe and Groen, Kaz and Verkleij, Christie P M and Frerichs, Kristine A and Papazian, Natalie and van Duin, Mark and van Beek, Gregory and Hoogenboezem, Remco and Baardemans, Thomas and Dal Collo, Giada and Stoetman, Elodie C G and Cosovic, Meliha and Twickler, Inoka and Rentenaar, Rosa and Eken, Merve and Homan-Weert, Paola M and Saraci, Elona and D'Agostino, Mattia and van der Velden, Vincent H J and Sanders, Mathijs A and Gay, Francesca and Broijl, Annemiek and Moreau, Philippe and Sonneveld, Pieter and Zweegman, Sonja and Mutis, Tuna and Cupedo, Tom and van de Donk, Niels W C J},
  title = {The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy},
  journal = {Blood},
  year = {2025},
  volume = {145},
  number = {25},
  pages = {3007--3014},
  doi = {10.1182/blood.2024026455}
}
Kostenlos starten →